E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Castration Resistent Prostate cancer |
|
E.1.1.1 | Medical condition in easily understood language |
castration resistent prostate cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Male diseases of the urinary and reproductive systems [C12] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess whether patients with castration resistant prostate cancer survive without their cancer getting worse (progression free survival) for longer than standard treatment, when receiving triamcinolone whilst continuing GnRH analog treatment and following failure of hormone therapy. This will be assessed by measuring PSA levels. |
|
E.2.2 | Secondary objectives of the trial |
1. Time to PSA progression
2. Time to symptomatic progression
3. CTC response at 28 days
4. To evaluate translational endpoints
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Histologically confirmed adenocarcinoma of the prostate
2. Progressive disease despite castration with an elevated PSA >5ng/ml (testosterone <1.5nmol/l or failure of GnRH analogue with peripheral anti-androgen if non-castrate level on GnRH alone)
3. ECOG performance status (PS) 0-3 and considered by responsible consultant suitable to undergo treatment
4. Males aged greater or equal 18
5. Patients who are able to understand their participation in the study and give written informed consent
|
|
E.4 | Principal exclusion criteria |
1. Contraindication to intramuscular injections
2. Unable to titrate medication for type 2 diabetes if deterioration in control on triamcinolone
3. Absolute contraindication to corticosteroids
4. Previous use of corticosteroids in prostate cancer
5. Previous chemotherapy for prostate cancer
6. Current participation in any other investigational drug study
7. History of a malignancy within 5 years except those treated with curative intent for skin cancer (other than melanoma)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression free survival |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Time from first administration of study drug to the first observation of disease
progression or death. |
|
E.5.2 | Secondary end point(s) |
Time to PSA progression, symptomatic progression, CTC response at 28 days
Translational endpoints: Effect of T887A and AR ccr on response to treatment.
Blood sample collection: SNP analysis for those involved in
androgen synthesis and metabolism |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Circulating tumour cell response evaluation at 28days |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial is defined as the date of the last patient visit of the last patient to complete the study or the date at which the last data point from the last patient, which was required for statistical analysis. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |